financetom
Business
financetom
/
Business
/
Here’s why it is imperative for cement industry to take adequate price hikes this quarter
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Here’s why it is imperative for cement industry to take adequate price hikes this quarter
Apr 11, 2023 11:28 PM

A high competitive intensity in a largely consolidated Indian cement industry led to inconsequential growth in the prices of cement in a seasonally strong quarter of Q4FY23. While the cement producers successfully achieved their goal of pushing volumes, margins were to be sacrificed. Albeit, cost deflation aided by the correction in petcoke, thermal coal and crude oil prices provided some cushion. Bringing respite to cement producers, imported coal price dipped in the past few months while imported petcoke price remained range-bound.

Share Market Live

NSE

This cyclical industry is in its strongest quarter now, benefiting from high construction and infrastructural activities along with CY2023 being a pre-election year where Government capex is usually at its peak.

Cost pressures are receding and focus now shifts to pricing. Recent dealer checks suggest a likelihood of escalation in cement prices by about Rs 10 per bag in April, varying across various regions in India. However, high level of inventories in distribution channel could tamper the full benefit of such price hikes.

Although, it shall be imperative to take adequate price hikes in April, compared with an average of about 2 percent discount offered in the month of March 2023 by cement producers to push volumes.

What could pose a risk to the cement price hikes this year is the commissioning of new capacities. Aggressive expansion plans by ACC and Ambuja Cement to increase its capacity to 140 MT by 2028 from the current 68 MT could create an unstable pricing environment. However, JPMorgan called these assumptions "too optimistic." JPMorgan India's Pinakin Parekh said the industry is witnessing a one-of-a-kind capacity expansion cycle and it is yet to be seen if the new capacity could create a lid on the price hikes this time around.

The timing of the merger of Adani Group's two cement companies could well be speculated, but it is noteworthy that a brownfield capex takes at least few months for successful execution. Hence, delayed timelines may imply that best part of the cycle is missed (pre-election year). Also, the company lays targets to achieve improvement in EBITDA per ton which could prompt at a low possibility of negative impact on industry pricing in the near term. What further works in favour of the cement industry today is the robust demand for urban housing which is at decadal low inventory. Nearly a quarter of cement demand is contributed by the urban housing segment, followed by another one-third demand from the rural housing segment. However, in a rising interest rate scenario it will be crucial for the current strong housing demand to continue gaining pace.

Brokerages do not expect a material earnings upgrade in the cement industry, however margins may recover in Q1FY24 amid cement price hikes and a drop in coal and petcoke costs. Evidently, construction and infrastructure activities need to continue their momentum in Q1FY24 so as to maintain the elevated demand for cement. The following quarter is seasonally subdued with the onset of monsoons and hence the possibility of price hikes then shall be slim. Amidst capacity additions, a balance in demand-supply needs to be optimal, so as to create a stable pricing environment for rest of the year.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy
Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy
Mar 20, 2024
11:01 AM EDT, 03/20/2024 (MT Newswires) -- Celularity ( CELU ) said Wednesday it submitted an application to the US Food and Drug Administration requesting an orphan drug designation for PDA-002 as a treatment for genetic muscle disorder facioscapulohumeral muscular dystrophy. The FDA has already approved the investigative new drug application for PDA-002 and Celularity ( CELU ) will start...
AAR Signs Multiyear Deal to Supply CFM56-5B Engine Surplus Material to Cebu Pacific
AAR Signs Multiyear Deal to Supply CFM56-5B Engine Surplus Material to Cebu Pacific
Mar 20, 2024
10:59 AM EDT, 03/20/2024 (MT Newswires) -- AAR (AIR) said Wednesday it has a multiyear agreement to provide surplus material for the CFM56-5B engine to Cebu Pacific. Financial details weren't disclosed. Under the accord, AAR said it will assist with the 30 scheduled shop visits for CFM56-5B engines that Cebu Pacific has scheduled throughout the contract period. Shares of ARR...
Cabaletta Bio Gets Orphan Drug Designation From FDA For Systemic Sclerosis Treatment
Cabaletta Bio Gets Orphan Drug Designation From FDA For Systemic Sclerosis Treatment
Mar 20, 2024
10:57 AM EDT, 03/20/2024 (MT Newswires) -- Cabaletta Bio ( CABA ) said Wednesday the US Food and Drug Administration has given orphan drug designation to CABA-201 to potentially treat systemic sclerosis. The candidate drug is being developed to treat autoimmune diseases driven by B cells, the company said, adding the clinical trial program has four phase 1/2 trials to...
New Fortress Energy Closes on Purchase of Electricity Supply Contract in Brazil
New Fortress Energy Closes on Purchase of Electricity Supply Contract in Brazil
Mar 20, 2024
11:00 AM EDT, 03/20/2024 (MT Newswires) -- New Fortress Energy ( NFE ) said Wednesday it has completed its acquisition of a 1.6-gigawatt capacity reserve electricity contract from a portfolio company of private equity firm Denham Capital. Under terms of the purchase agreement, New Fortress will issue a undisclosed amount of its series A convertible preferred stock to Denham Capital...
Copyright 2023-2026 - www.financetom.com All Rights Reserved